Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients

Author： Naoi Yasuto  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.128, Iss.3, 2011-08, pp. : 633-641

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

By Eiermann W.   Rezai M.   Kmmel S.   Khn T.   Warm M.   Friedrichs K.   Schneeweiss A.   Markmann S.   Eggemann H.   Hilfrich J.   Jackisch C.   Witzel I.   Eidtmann H.   Bachinger A.   Hell S.   Blohmer J.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 618-624

Oxford University Press

Access to resources Recommend Favorite

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer

By Lamond Nathan   Skedgel Chris   Rayson Daniel   Lethbridge Lynn   Younis Tallal  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1115-1123

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic variables in node-negative and node-positive breast cancer - Introduction

By Gasparini G.  

Breast Cancer Research and Treatment, Vol. 51, Iss. 3, 1998-10 ,pp. : 193-194

Springer Publishing Company

Access to resources Recommend Favorite

Inflammatory cells in node-negative breast cancer

By Löfdahl Britta   Ahlin Cecilia   Holmqvist Marit   Holmberg Lars   Zhou Wenjing   Fjällskog Marie-Louise   Amini Rose-Marie  

Acta Oncologica, Vol. 51, Iss. 5, 2012-05 ,pp. : 680-686

Informa Healthcare

Access to resources Recommend Favorite

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

By Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 775-784

Springer Publishing Company

Access to resources Recommend Favorite